![glp-1 receptor agonists should be avoided in patients with Weight-Loss Medication Glucagon-like peptide-1 (GLP-1) (semaglutide [Wegovy, Ozempic, Rybelsus]) and dual incretin agonists (tirzepatide [Zepbound, Mounjaro]) are popular treatments for obesity. The authors discuss the kind of GLP-1 receptor agonists and next-generation](https://lookaside.fbsbx.com/lookaside/crawler/media/?media_id=1050961973852737)
glp-1 receptor agonists should be avoided in patients with
Shipping Estimate
glp-1 receptor agonists should be avoided in patients with Weight-Loss Medication Glucagon-like peptide-1 (GLP-1) (semaglutide [Wegovy, Ozempic, Rybelsus]) and dual incretin agonists (tirzepatide [Zepbound, Mounjaro]) are popular treatments for obesity. The authors discuss the kind of GLP-1 receptor agonists and next-generation
Shipping Estimate
USA
- USA
- CAN
- USA
- CAN
Ships within 48 hours · Estimated delivery Aug 7 - Aug 12
![glp-1 receptor agonists should be avoided in patients with Weight-Loss Medication Glucagon-like peptide-1 (GLP-1) (semaglutide [Wegovy, Ozempic, Rybelsus]) and dual incretin agonists (tirzepatide [Zepbound, Mounjaro]) are popular treatments for obesity. The authors discuss the kind of GLP-1 receptor agonists and next-generation](https://media.springernature.com/m685/springer-static/image/art%3A10.1038%2Fs41581-025-01036-y/MediaObjects/41581_2025_1036_Fig1_HTML.png)
![glp-1 receptor agonists should be avoided in patients with Weight-Loss Medication Glucagon-like peptide-1 (GLP-1) (semaglutide [Wegovy, Ozempic, Rybelsus]) and dual incretin agonists (tirzepatide [Zepbound, Mounjaro]) are popular treatments for obesity. The authors discuss the kind of GLP-1 receptor agonists and next-generation](https://ars.els-cdn.com/content/image/1-s2.0-S2667368124000238-ga1.jpg)
![glp-1 receptor agonists should be avoided in patients with Weight-Loss Medication Glucagon-like peptide-1 (GLP-1) (semaglutide [Wegovy, Ozempic, Rybelsus]) and dual incretin agonists (tirzepatide [Zepbound, Mounjaro]) are popular treatments for obesity. The authors discuss the kind of GLP-1 receptor agonists and next-generation](https://media.springernature.com/lw685/springer-static/image/art%3A10.1038%2Fs41591-024-03412-w/MediaObjects/41591_2024_3412_Fig6_HTML.png)
![glp-1 receptor agonists should be avoided in patients with Weight-Loss Medication Glucagon-like peptide-1 (GLP-1) (semaglutide [Wegovy, Ozempic, Rybelsus]) and dual incretin agonists (tirzepatide [Zepbound, Mounjaro]) are popular treatments for obesity. The authors discuss the kind of GLP-1 receptor agonists and next-generation](https://www.mdpi.com/jcm/jcm-15-03330/article_deploy/html/images/jcm-15-03330-g002-550.jpg)
![glp-1 receptor agonists should be avoided in patients with Weight-Loss Medication Glucagon-like peptide-1 (GLP-1) (semaglutide [Wegovy, Ozempic, Rybelsus]) and dual incretin agonists (tirzepatide [Zepbound, Mounjaro]) are popular treatments for obesity. The authors discuss the kind of GLP-1 receptor agonists and next-generation](https://i0.wp.com/www.cardionerds.com/wp-content/uploads/2024/04/Clinical-Implementation-of-GLP-1-Receptor-Agonists-with-Dr.-Neha-Pagidapati.png?resize=1200%2C600&ssl=1)
